EPICETUS STUDY
Research type
Research Study
Full title
Study to assEss the PractIcal Cinical UTility of the NuQ.® H3.1 Nucleosome Levels in Adult Patients with Sepsis to facilitate Early Diagnosis and Prognostication. (EPICETUS)
IRAS ID
324730
Contact name
Andrew Retter
Contact email
Sponsor organisation
Guy's and St. Thomas' NHS Foundation Trust
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
324730,
Duration of Study in the UK
1 years, 6 months, 1 days
Research summary
The purpose of this study is to record the evolution of H3.1 nucleosome levels in patients with sepsis and compare the evolution in their trajectory to patients exposed to the sterile surgical insult of cardiac surgery. We are studying how the NU.QTM H3.1 assay performs as a marker of sepsis and septic shock with multiple organ failure. To both help with making a diagnosis and monitoring a patient’s condition. It’s hoped that the faster access and turnaround of these results will in the future enable the more timely and targeted treatment of patients with sepsis. Improving the outcome of patients with a reduction in mortality and sepsis related morbidity.
REC name
London - Bromley Research Ethics Committee
REC reference
23/LO/0818
Date of REC Opinion
18 Oct 2023
REC opinion
Further Information Favourable Opinion